سعر سيزولو 200مجم/مل نقط للفم 2022

Seizolow 200 mg/ml oral drops by Alexandria (Egypt); concentrated sodium valproate antiepileptic oral drops.

• Serious adverse reactions described in the label include hepatic failure, birth defects, decreased IQ after in-utero exposure, pancreatitis, hyperammonaemic encephalopathy, suicidal behaviour and ideation, bleeding and other haematopoietic disorders, hypothermia and DRESS.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Hepatic disease or significant hepatic dysfunction; known mitochondrial disorders caused by POLG mutations (e.g. Alpers-Huttenlocher syndrome) and suspected POLG-related disorder in children under 2 years; known hypersensitivity; urea cycle disorders.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Migraine prophylaxis: contraindicated in pregnant women and in women of childbearing potential not using effective contraception.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: hepatotoxicity including fatal hepatic failure, usually in the first 6 months; children under 2 years and patients with mitochondrial disorders are at higher risk; perform liver tests before therapy and at frequent intervals thereafter.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Boxed warning: fetal risk - neural tube defects, other major malformations and decreased IQ; for epilepsy, do not use in women who are pregnant or plan pregnancy unless other medications have failed or are unacceptable.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Boxed warning: life-threatening pancreatitis, including haemorrhagic cases with rapid progression.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Valproate is partly eliminated as a keto-metabolite and may give false urine ketone test results; altered thyroid function tests have been reported.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, phenytoinConcentrations of these drugs may be affected as the valproate dose is titrated upward.DailyMed (U.S. National Library of Medicine)
• RufinamidePatients stabilised on rufinamide should begin valproate at a low dose and titrate to a clinically effective dose.DailyMed (U.S. National Library of Medicine)

• Maternal valproate use increases the risk of congenital malformations, particularly neural tube defects such as spina bifida, and of decreased IQ; for epilepsy it should not be used in pregnancy unless other medications have failed; women who become pregnant should not stop it abruptly (risk of status epilepticus). Encourage enrolment in the NAAED Pregnancy Registry.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Valproate is excreted in human milk (1-10% of maternal serum levels); weigh benefits of breastfeeding against risks and monitor the infant for signs of liver damage (jaundice, unusual bruising or bleeding).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Serum liver tests before and at frequent intervals during therapy; plasma valproate and concomitant antiepileptic drug levels early in therapy; monitor breastfed infants for jaundice and unusual bruising or bleeding.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Sodium valproate: Valproate mechanism has not been established; its activity in epilepsy has been related to increased brain GABA concentrations.